Cutaneous side-effects during therapy of melanoma by vemurafenib
Introduction. Vemurafenib is a selective inhibitor of serine-threonine kinase BRAF used in the treatment of advanced melanoma with BRAF mutation. Effectiveness of this drug was confirmed in a large clinical trial, which led to the increase of its usage. During treatment with vemurafenib, particular...
Saved in:
Main Authors: | Anna Ankudowicz (Author), Urszula Brzezicka-Ciach (Author), Bożena Wenska (Author) |
---|---|
Format: | Book |
Published: |
Termedia Publishing House,
2015-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma
by: Hongmei Cui, et al.
Published: (2021) -
Vemurafenib and cutaneous adverse events - report of five cases
by: Giselle de Barros Silva, et al.
Published: (2015) -
Indolium 1 Exerts Activity against Vemurafenib-Resistant Melanoma In Vivo
by: Rakan Radi, et al.
Published: (2022) -
Dermatomyositis as a manifestation of cancer
by: Katarzyna Przekazińska-Boager, et al.
Published: (2014) -
Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma
by: Swaika A, et al.
Published: (2014)